Scripps Research is charting new territory with its Calibr division, a drug discovery and drug development group within the research institute that is advancing its own experimental treatments.

After its disappointing Rova-T flop last month, AbbVie is shoring up its solid tumor bets with a freshly inked research deal that should elicit new strategies for tumor attack.